Journal article
Temporal Trajectory of B-Type Natriuretic Peptide in Patients with CKD Stages 3 and 4, Dialysis, and Kidney Transplant
Matthew A Roberts, David L Hare, Ken Sikaris, Francesco L Ierino
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | AMER SOC NEPHROLOGY | Published : 2014
DOI: 10.2215/CJN.08640813
Abstract
BACKGROUND AND OBJECTIVES: B-type natriuretic peptide (BNP) concentration predicts outcome in patients undergoing dialysis. Because survival and cardiovascular risk change across the CKD continuum, serial changes in BNP were compared in patients at different CKD stages and after kidney transplantation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients with CKD stages 3 and 4 (CKD 3-4), dialysis patients, and kidney transplant recipients (KTRs) from one center had two measurements of BNP taken a median of 161 days apart in 2003-2004 and were followed until July 2012. Both BNP-32 (Triage BNP; Biosite Diagnostics) and NT-BNP-76 (proBNP; Roche Diagnostics) were assayed. The interaction bet..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia Health Professional Training Fellowship
Funding Acknowledgements
M.A.R. is supported by a National Health and Medical Research Council of Australia Health Professional Training Fellowship (628902). This study was supported by unrestricted grants from Amgen, Bristol-Myers Squibb, Janssen-Cilag, and Servier. Abbott Diagnostics, Roche Diagnostics Australia, and Medtec Products Australia provided assay kits at various levels of discount for the biochemical assays.